Canada Clinical Nutrition for Cancer Care Market Analysis

Canada Clinical Nutrition for Cancer Care Market Executive Summary

The Canada Clinical Nutrition for Cancer Care Market was valued at $450.4 Mn in 2023 and is predicted to grow at a CAGR of 5.04% from 2023 to 2030, to $635.5 Mn by 2030

Clinical nutrition for cancer care is a specialized field focusing on providing optimal nutritional support to patients throughout their cancer journey. It goes beyond simply “eating healthy” and involves a personalized approach to address the unique nutritional needs of each patient. A registered dietitian or other qualified healthcare professional usually assess the patient’s nutritional status. Based on the assessment, a personalized plan is created to meet the patient’s individual needs. Nutritional deficiencies are prevalent among cancer patients due to treatment side effects, altered metabolism, and decreased appetite. Clinical nutrition interventions play a crucial role in improving treatment tolerance as adequate nutrition can help patients tolerate chemotherapy and radiation therapy better, potentially reducing side effects and allowing for completion of treatment plans. Also, it maintains strength and immunity as proper nutrition helps patients maintain muscle mass, fight infections, and recover faster from surgery. Lastly, it enhances the quality of life since nutritional support can improve fatigue, appetite, and overall well-being, leading to a better quality of life during cancer treatment.

Advancements in medical nutrition therapy have led to the development of specialized oral nutritional supplements (ONS) and enteral feeding formulas. These products provide concentrated nutrients and can be crucial for patients struggling to meet their nutritional needs through regular diet alone. Parenteral nutrition remains an option for patients unable to tolerate oral or enteral feeding. Overall, clinical nutrition for cancer care plays a vital role in optimizing patient outcomes by ensuring they receive the necessary nutrients to support their body throughout treatment.

Malnutrition is a common feature in cancer patients and is the consequence of both the presence of the tumour and the medical and surgical anticancer treatments. Malnutrition negatively impacts on quality of life and treatment toxicities, and it has been estimated that up to 10% to 20% of cancer patients die due to consequences of malnutrition rather than for the tumour itself. Thus, nutrition plays a crucial role in multimodal cancer care. Therefore, the Canada Clinical Nutrition for Cancer Care Market is driven by significant factors such as the increasing prevalence of cancer, increased awareness and education, and increasing healthcare expenditure. However, complexity of cancer care, reduced patient compliance, and stringent regulatory guidelines and approval process in the Canada restrict the growth and potential of the market.

The major players of the Canada Clinical Nutrition for Cancer Care Market are Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, Pfizer and Fresenius Kabi, among others. Abbott Nutrition is a division of Abbott Laboratories, specializing in nutritional products for infants, children, and adults, including those with medical conditions. Key products include Ensure, Jevity, and Glucerna, which cater to different nutritional needs and conditions, including cancer care.

Market Dynamics

Market Growth Drivers

Increasing Prevalence of Cancer: Cancer remains the leading cause of death in Canada. An estimated 2 in 5 Canadians will be diagnosed with cancer in their lifetime and about 1 in 4 will die from cancer. As the population ages and lifestyle risks like smoking persist, the number of new cancer cases diagnosed each year will continue to rise. Researchers estimated that there would be 247,100 new cancer cases and 88,100 cancer deaths in Canada in 2024. This translates to a larger patient population requiring specialized nutritional support during treatment, which in turn drives the Clinical Nutrition for Cancer Care Market further.

Increased awareness and education: Increased awareness among healthcare providers, patients, and caregivers about the critical role of nutrition in cancer care drives demand for clinical nutrition products. Training programs and continuous education for oncologists, dietitians, and nurses on the benefits of clinical nutrition ensure that these professionals recommend and administer appropriate nutritional interventions to their patients. Increased awareness and education significantly contribute to the growth of the clinical nutrition market for cancer care by empowering patients, informing healthcare professionals, influencing public health policies, and driving research and product development. As more stakeholders recognize the critical role of nutrition in cancer treatment and recovery, the demand for clinical nutrition products continues to rise, expanding the market and improving patient outcomes.

Increasing Healthcare Expenditure: Higher healthcare expenditure allows for greater investment in R&D of advanced cancer treatments and nutritional products. This includes creating specialized formulas tailored to the needs of cancer patients, improving the efficacy and availability of clinical nutrition solutions. With more funding, healthcare providers can offer the latest cancer therapies, which often necessitate comprehensive nutritional support to manage side effects and enhance patient recovery. Increased spending leads to the development and modernization of hospitals and cancer treatment centres, equipped with the necessary infrastructure to provide comprehensive cancer care, including clinical nutrition services. Expanded healthcare budgets support the growth of homecare services, which include the delivery of clinical nutrition to cancer patients at home, making it more convenient and accessible. Thus, increased healthcare expenditure leads to the growth of US Clinical Nutrition for Cancer Care Market.

Market Restraints

Complexity of Cancer Care: Cancer care often involves a multidisciplinary team of oncologists, surgeons, radiologists, nurses, and dietitians. Coordinating the integration of clinical nutrition into comprehensive care plans can be complex and sometimes overlooked. Cancer patients have highly individualized nutritional needs based on their type of cancer, treatment regimen, and overall health. Creating and delivering personalized nutrition plans can be complex and resource-intensive. Also, side effects of cancer treatments can affect patients’ ability to tolerate certain nutritional products, leading to non-compliance or suboptimal nutrition. The complexity of managing multiple aspects of cancer care can lead to low patient compliance with nutritional recommendations, especially if patients are overwhelmed by their treatment regimen. Thus, the complexity of cancer care introduces several challenges that can reduce the market growth of clinical nutrition for cancer care.

Reduced Patient Compliance: Patient compliance is crucial for the effectiveness of nutritional interventions in cancer care. When patient compliance is low, it can significantly reduce the market of clinical nutrition for cancer care in several ways. When patients do not adhere to prescribed nutritional regimens, the expected therapeutic benefits are diminished. This can lead to poorer health outcomes, undermining the perceived value and efficacy of clinical nutrition products. If clinical nutrition products are perceived as ineffective due to non-compliance, healthcare providers may be less likely to recommend them, and patients may be less likely to use them, reducing overall demand. Non-compliance can lead to negative patient experiences if they do not see the expected improvements in their condition. This can result in dissatisfaction and a lack of trust in clinical nutrition products. Negative experiences can spread through word of mouth or online reviews, discouraging other patients and caregivers from using clinical nutrition products.

Stringent Regulatory Guidelines and Approval Process: The process for gaining approval from the regulatory body of Canada can be very length and complex, often taking several years. This delay can slow the introduction of new clinical nutrition products to the market, hindering the ability to meet current patient needs promptly. Next, the high cost and risk associated with meeting regulatory standards can make companies more conservative in their innovation efforts. They might focus on modifying existing products rather than developing entirely new ones, limiting the variety and potential effectiveness of clinical nutrition products available to cancer patients. For niche products, particularly those targeting rare conditions or specific cancer-related nutritional needs, the potential return on investment might not justify the high costs of regulatory compliance, leading to fewer products being developed. While stringent regulatory approval and guidelines are essential for ensuring the safety and efficacy of clinical nutrition products, they can also act as significant barriers to market growth. These regulations can lead to longer time-to-market, higher costs, reduced innovation, and limited competition, all of which can decrease the availability and affordability of clinical nutrition products for cancer care.

Regulatory Landscape and Reimbursement Scenario

The regulatory body in charge of policing a range of medical goods and services is the Health Canada. Foods, pharmaceuticals, medical equipment, biologics, natural health products, and other health products are all under the purview of Health Canada. Health Canada oversees the safety, effectiveness, and quality of all pharmaceutical medications intended for human use in Canada, both before and following their entry into the Canadian market, under the Food and Drugs Act.

The Department carries out this task by combining monitoring, scientific evaluation, compliance, and enforcement actions. It seeks to guarantee that people who require information about safety issues are informed and that the general public has prompt access to pharmaceuticals that are both safe and effective. Some of the responsibilities of the Health Canada include: Enforcing the pharmaceutical industry’s compliance with regulations, such as those pertaining to clinical trials, drug manufacturing, and the reporting of adverse drug reactions; reviewing clinical trial applications; reviewing drug submissions from manufacturers for market authorization and post-market changes; monitoring the safety of drugs in the Canadian market and informing the public and health care professionals about safety risks.

Through the Canada Health Transfer (CHT), the federal government distributes money to the states, territories, and provinces. Each province’s share of financing is decided by a complicated system that takes into account factors including population, health care requirements, and past expenditure trends. The costs of hospital stay, doctor visits, diagnostic tests, and some prescription drugs are then covered by the public healthcare insurance programs that are managed by the provinces and territories.

Competitive Landscape

Key Players

Here are some of the major key players in the Canada Clinical Nutrition for Cancer Care Market:

• Nestlé Health Science
• Abbott Nutrition
• Pfizer
• B. Braun Melsungen AG
• Fresenius Kabi
• Danone Nutrica
• Baxter International Inc.
• Victus Inc.
• Mead Johnson Nutrition
• Aymes